In early October, the U.S. Food and Drug Administration approved Paratek Pharmaceuticals’ new antibiotic Nuzyra, which kills bacteria associated with skin and lung infections.
The approval was notable because there are so few new antibiotics coming onto the market, , says journalist Maryn McKenna in Wired magazine, largely because most drug companies don’t think antibiotics — which have wiped out the threat of many infectious diseases — to be worth the investment.
The problem is a unique business and policy dilemma for society. Continue reading
For three years, the Centers for Medicare & Medicaid Services (CMS) have penalized hospitals when the institutions show unacceptably high rates of potentially avoidable complications, such as blood clots, bed sores, and infections, Jordan Rau reported last month for Kaiser Health News.
The federal agency this year added penalties for two hospital-acquired infections that result from germs resistant to antibiotics: methicillin-resistant Staphylococcus aureus (known as MRSA) and Clostridium difficile (C. diff). Continue reading
As senior quality editor for HealthLeaders Media for more than six years, Cheryl Clark wrote more than 1,300 stories about hospitals’ efforts to improve quality and safety and related issues.
Rates of sepsis seemed to be one more dirty little hospital horror to explore, one that the Joint Commission said cost hospitals about $16.7 billion annually. Yet hospitals’ efforts to tackle it seemed hidden behind improvement initiatives attracting more attention, such as reducing hospital-acquired infections, and preventable readmissions, lowering emergency room wait times and raising patient experience scores.
The story she wrote for the June 2014 issue of HealthLeaders’ print magazine, on how U.S. hospitals are improving recognition and treatment of sepsis — which is diagnosed in 750,000 patients a year and kills 40 percent — won the 2015 National Institute of Health Care Management prize in the trade print category. They said the story was “most likely to save a life.”
In a new article for AHCJ, she explains how she did her reporting, despite a lack of data and sources who didn’t want to talk. Read more.